New NDF Report: DXB

Team DXB,

Stuart Roberts from NDF has released an update note..

http://dimerix.com/wp-content/uploads/2016_10_18_dimerix_update_report_from_ndf.pdf

He is still very positive on the stock and maintains his 4c price target.

Few interesting comments in particular..

" analysis. We think this encouraging data provides strong, albeit early validation of Dimerix’s approach of treatment kidney disease via a drug that hits the AT1R/CCR2 GPCR heteromer."

We argue that if further patients in Dimerix’s current study can register a >50% reduction in proteinuria by keeping patients on irbesartan and adding propagernaium, the drug can be said to be broadly competitive with Retrophin’s drug. One can also make the case that, potentially, Dimerix has a superior therapy because it does not take patients off the current standard-of care for the management of hypertension, which is what around four-fifths of patients with chronic kidney disease will have as a co-morbidity5 .

We believe the company will be in a position to report further interim data on the dose-ranging study in the current quarter, followed by full data in mid-2017.

Stay tuned folks!

A.